Amundi
NPCE icon

Amundi’s Neuropace NPCE Stock Holding History

Amundi’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-81,157
Closed -$1.29M – 1711
2021
Q3 		$1.29M Buy
+81,157
New +$1.7M ﹤0.01% 1254

Other funds holding NPCE

KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Amundi's NPCE Position: Q4 2021 in Review

Amundi sold out of Neuropace (NPCE) in Q4 2021, closing a stake of 81,157 shares — an estimated $1.29M sold.

Amundi first reported a position in NPCE in Q3 2021 and held it in 1 quarter. The position peaked at $1.29M in Q3 2021. 41 funds tracked by Wall St. Rank hold NPCE as of Q4 2021.

  • Amundi reported no remaining Neuropace position as of Q4 2021 after selling out during the quarter.
  • Amundi sold 81,157 Neuropace shares in Q4 2021, an estimated $1.29M.
  • Amundi first reported a position in Neuropace in Q3 2021 and held it in 1 quarter.
  • Amundi's Neuropace position peaked at $1.29M in Q3 2021.
  • 41 funds tracked by Wall St. Rank held Neuropace as of Q4 2021.

Based on Amundi's 13F filing for Q4 2021, filed 14 Feb 2022.